Supernus Pharmaceuticals, Inc. (SUPN) Income Statement
SUPN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSUPN revenue and net income
Where SUPN's revenue goes
2025Each bar shows an amount and its share of revenue. SUPN kept −5.4% of revenue as net income.
SUPN profit margins
SUPN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +8.6% | +2.5% | +6.7% | +17.4% |
| Gross profit | +10.4% | +3.6% | +6.6% | +16.8% |
| Operating income | −145.1% | — | — | — |
| Net income | −152.2% | — | — | — |
| EPS (diluted) | +10.9% | +23.2% | +3.8% | +24.4% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SUPN quarterly EPS vs estimates
Supernus Pharmaceuticals beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 3, 2026 (estimate $0.66).
SUPN income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $719.0M | $661.8M | $607.5M | $667.2M | $579.8M | $520.4M | $392.8M | $408.9M | $302.2M | $215.0M |
| Cost of revenue | $74.6M | $77.9M | $83.8M | $87.2M | $75.1M | $52.5M | $16.7M | $15.4M | $15.2M | $12.0M |
| Gross profit | $644.4M | $583.9M | $523.7M | $580.0M | $504.7M | $467.9M | $376.1M | $393.5M | $287.0M | $203.0M |
| Research & development | $106.2M | $108.8M | $91.6M | $74.6M | $90.5M | $76.0M | $69.1M | $89.2M | $49.6M | $42.8M |
| Sales, general & admin | $485.6M | $335.8M | $336.4M | $377.2M | $304.8M | $200.7M | $158.4M | $159.9M | $137.9M | $106.0M |
| Total operating expenses | $681.3M | $502.2M | $529.0M | $533.9M | $418.7M | $294.2M | $227.5M | $249.1M | $187.5M | $148.8M |
| Operating income | −$36.9M | $81.7M | −$5.3M | $46.1M | $86.0M | $173.7M | $148.6M | $144.4M | $99.5M | $54.2M |
| Interest income | $13.3M | $16.2M | $10.9M | $21.7M | $10.6M | $18.7M | $21.6M | $13.8M | $2.9M | $1.5M |
| Interest expense | $0 | $0 | $2.4M | $7.1M | $23.4M | $23.8M | $22.7M | $18.1M | $1.6M | $5.1M |
| Income before taxes | −$49.0M | $97.9M | $2.8M | $60.7M | $73.2M | $168.6M | $147.5M | $140.2M | $100.6M | $50.4M |
| Income taxes | −$10.5M | $24.0M | $1.5M | $32,000 | $19.8M | $41.7M | $34.4M | $29.2M | $43.3M | −$40.9M |
| Net income | −$38.5M | $73.9M | $1.3M | $60.7M | $53.4M | $127.0M | $113.1M | $111.0M | $57.3M | $91.2M |
| EBITDA | $42.5M | $178.3M | $90.0M | $153.4M | $129.2M | $210.5M | $176.9M | $151.5M | $107.7M | $56.6M |
| EPS (diluted) | $2.84 | $2.56 | $2.30 | $1.52 | $0.98 | $2.36 | $2.11 | $2.06 | $1.26 | $1.02 |
| Gross margin | 89.6% | 88.2% | 86.2% | 86.9% | 87.1% | 89.9% | 95.8% | 96.2% | 95.0% | 94.4% |
| Operating margin | −5.1% | 12.3% | −0.9% | 6.9% | 14.8% | 33.4% | 37.8% | 35.3% | 32.9% | 25.2% |
| Net margin | −5.4% | 11.2% | 0.2% | 9.1% | 9.2% | 24.4% | 28.8% | 27.1% | 19.0% | 42.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $219.1M | $207.7M | $211.6M | $192.1M | $165.5M | $149.8M | $174.2M | $175.7M | $168.3M | $143.6M | $164.3M | $153.9M |
| Cost of revenue | $33.7M | $23.4M | $23.0M | $19.0M | $16.8M | $15.8M | $26.1M | $17.6M | $17.9M | $16.3M | $19.6M | $19.6M |
| Gross profit | $185.4M | $184.3M | $188.6M | $173.1M | $148.6M | $134.1M | $148.1M | $158.1M | $150.4M | $127.3M | $144.7M | $134.3M |
| Research & development | $29.5M | $39.4M | $27.8M | $29.4M | $22.1M | $26.9M | $28.6M | $29.0M | $26.2M | $24.9M | $23.3M | $22.7M |
| Sales, general & admin | $133.6M | $125.2M | $122.4M | $179.7M | $93.6M | $89.9M | $79.4M | $69.8M | $85.9M | $86.5M | $81.3M | $82.7M |
| Total operating expenses | $243.4M | $192.6M | $174.7M | $233.4M | $136.5M | $144.3M | $126.7M | $117.3M | $127.8M | $130.5M | $145.7M | $126.1M |
| Operating income | −$58.0M | −$7.4M | $13.8M | −$60.2M | $12.1M | −$10.3M | $21.4M | $40.8M | $22.6M | −$3.2M | −$996,000 | $8.1M |
| Interest income | $2.6M | $2.4M | $2.0M | $2.3M | $4.5M | $4.4M | $5.0M | $4.1M | $3.7M | $3.4M | $2.0M | $1.8M |
| Interest expense | $2.3M | — | — | — | $0 | — | $0 | $0 | $0 | $0 | $4.8M | $0 |
| Income before taxes | −$57.6M | −$6.0M | −$1.9M | −$58.0M | $16.7M | −$5.8M | $26.4M | $44.9M | $26.3M | $243,000 | $990,000 | $9.9M |
| Income taxes | $723,000 | −$3.7M | $2.2M | −$12.8M | −$5.8M | $6.0M | $11.1M | $6.4M | $6.4M | $119,000 | −$185,000 | $25.9M |
| Net income | −$58.4M | −$2.3M | −$4.1M | −$45.1M | $22.5M | −$11.8M | $15.3M | $38.5M | $19.9M | $124,000 | $1.2M | −$16.0M |
| EBITDA | −$29.6M | $20.2M | $26.7M | −$33.1M | $38.0M | $17.8M | $45.2M | $65.0M | $38.9M | $16.5M | $22.7M | $31.7M |
| EPS (diluted) | $0.39 | $0.21 | $0.88 | $0.61 | $0.91 | $0.44 | $0.55 | $1.10 | $0.67 | $0.24 | $0.89 | $0.24 |
| Gross margin | 84.6% | 88.7% | 89.1% | 90.1% | 89.8% | 89.5% | 85.0% | 90.0% | 89.4% | 88.6% | 88.1% | 87.3% |
| Operating margin | −26.5% | −3.6% | 6.5% | −31.4% | 7.3% | −6.8% | 12.3% | 23.2% | 13.4% | −2.2% | −0.6% | 5.3% |
| Net margin | −26.6% | −1.1% | −1.9% | −23.5% | 13.6% | −7.9% | 8.8% | 21.9% | 11.8% | 0.1% | 0.7% | −10.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SUPN's financial statements (latest annual report filed March 2, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SUPN financial results
In fiscal year 2025 (ended December 31, 2025), Supernus Pharmaceuticals reported revenue of $719.0 million, up 8.6% from the year before. It had a net loss of $38.5 million, a net profit margin of −5.4%. Diluted earnings per share came to $2.84. Over five years revenue grew at an average rate of 6.7% a year.
See the SUPN stock overview for the latest quote and news, or the SUPN chart for price history and technical indicators.
SUPN income statement FAQ
What is Supernus Pharmaceuticals's annual revenue?
Supernus Pharmaceuticals reported total revenue of $719.0 million for fiscal year 2025, which ended on December 31, 2025. That was up 8.6% from $661.8 million the previous year.
Is Supernus Pharmaceuticals profitable?
No. Supernus Pharmaceuticals reported a net loss of $38.5 million in fiscal 2025, a net profit margin of −5.4%; its operating margin was −5.1%.
What is Supernus Pharmaceuticals's gross margin?
Supernus Pharmaceuticals's gross margin was 89.6% in fiscal 2025: for every $100 of revenue, Supernus Pharmaceuticals kept $90 after the direct cost of its products and services.
How much does Supernus Pharmaceuticals spend on research and development?
Supernus Pharmaceuticals spent $106.2 million on research and development in fiscal 2025, 14.8% of revenue.
How fast is Supernus Pharmaceuticals growing?
Revenue grew 6.7% a year on average over the last five fiscal years, from $520.4 million to $719.0 million.
What are Supernus Pharmaceuticals's earnings per share?
Supernus Pharmaceuticals earned $2.84 per diluted share in fiscal 2025, compared with $2.56 a year earlier.
When will Supernus Pharmaceuticals report its next earnings?
Supernus Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens.
When does Supernus Pharmaceuticals's fiscal year end?
Supernus Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 2, 2026.